Yubao Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yubao Wang has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Jing Feng
Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China
13 shared publications Changqing Yang
Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China
4 shared publicationsJau-Shyong Hong
Neurobiology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, Durham, NC, 27709, USA
4 shared publicationsLei Yang
Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China
4 shared publicationsShuangyu Han
Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, No. 154 Anshan Street, Heping District, Tianjin, 300052, China
4 shared publicationsZhan Zhao
Respiratory Department, Tianjin Medical University General Hospital, Tianjin, China
4 shared publications
Latest Publications
- 24 September 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1035, 179372
Targeting the Snail1–ATGL–ferroptosis–EMT axis via AKT–GSK3β signaling: Low-dose colchicine attenuates idiopathic pulmonary fibrosis
- 24 September 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1035, 179372
Targeting the Snail1–ATGL–ferroptosis–EMT axis via AKT–GSK3β signaling: Low-dose colchicine attenuates idiopathic pulmonary fibrosis
- 16 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (867)
Unanticipated global emergence and evolution of Pneumocystis jirovecii mutations and resistance driven by a human-targeted drug
Nearly all known cases of antimicrobial resistance have been linked to agents that directly target microbes. This paradigm overlooks other drivers of microbial evolution and resistance. Here, we report compelling evidence of resistance-associated mutations in Pneumocystis jirovecii , a high-priority fungal pathogen designated by WHO as having unknown resistance. These mutations emerged under selective pressure from mycophenolic acid (MPA), a widely used immunosuppressant not used for Pneumocystis pneumonia (PCP) treatment. A potent inhibitor of inosine monophosphate dehydrogenase (IMPDH), MPA has been linked to altered P. jirovecii susceptibility in solid organ transplant (SOT) recipients. Genetic analysis of 163 P. jirovecii samples from PCP outbreaks in SOT recipients and nontransplant controls across six countries identified six impdh mutations, four of which were previously unreported. These mutations showed strong associations with prior MPA exposure, geographic segregation, and temporal shifts. They arose independently in 11 distinct strains worldwide between 2005 and 2019, with evidence of switching within and between strains, suggesting ongoing adaptive evolution. Structural modeling predicted that these mutations reduced IMPDH stability and MPA binding; accordingly, all mutations conferred MPA resistance in enzyme inhibition assays. Our findings uncover the unanticipated global emergence of multiple resistance-associated mutations in P. jirovecii driven by a human-targeted immunosuppressant, likely conferring a survival advantage in SOT recipients and facilitating transmission and outbreaks. These results challenge the current status quo on P. jirovecii ’s unknown resistance, calling for reevaluating immunosuppressive strategies and infection control measures and highlighting the broader potential for other pathogens to evolve under selective pressures imposed by human-targeted therapies.
- 16 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (867)
Unanticipated global emergence and evolution of Pneumocystis jirovecii mutations and resistance driven by a human-targeted drug
Nearly all known cases of antimicrobial resistance have been linked to agents that directly target microbes. This paradigm overlooks other drivers of microbial evolution and resistance. Here, we report compelling evidence of resistance-associated mutations in Pneumocystis jirovecii , a high-priority fungal pathogen designated by WHO as having unknown resistance. These mutations emerged under selective pressure from mycophenolic acid (MPA), a widely used immunosuppressant not used for Pneumocystis pneumonia (PCP) treatment. A potent inhibitor of inosine monophosphate dehydrogenase (IMPDH), MPA has been linked to altered P. jirovecii susceptibility in solid organ transplant (SOT) recipients. Genetic analysis of 163 P. jirovecii samples from PCP outbreaks in SOT recipients and nontransplant controls across six countries identified six impdh mutations, four of which were previously unreported. These mutations showed strong associations with prior MPA exposure, geographic segregation, and temporal shifts. They arose independently in 11 distinct strains worldwide between 2005 and 2019, with evidence of switching within and between strains, suggesting ongoing adaptive evolution. Structural modeling predicted that these mutations reduced IMPDH stability and MPA binding; accordingly, all mutations conferred MPA resistance in enzyme inhibition assays. Our findings uncover the unanticipated global emergence of multiple resistance-associated mutations in P. jirovecii driven by a human-targeted immunosuppressant, likely conferring a survival advantage in SOT recipients and facilitating transmission and outbreaks. These results challenge the current status quo on P. jirovecii ’s unknown resistance, calling for reevaluating immunosuppressive strategies and infection control measures and highlighting the broader potential for other pathogens to evolve under selective pressures imposed by human-targeted therapies.
- Open Access
A novel proliferative candidate genes panel for idiopathic pulmonary fibrosis: insights from integrated bulk and single-cell RNA sequencing
Background: Idiopathic pulmonary fibrosis (IPF) remains a fatal interstitial lung disease with limited diagnostic specificity and therapeutic options. This study integrates bulk and single-cell RNA sequencing (RNA-seq) to identify novel biomarkers and elucidate molecular mechanisms underlying IPF pathogenesis. Methods: We prospectively enrolled 14 treatment-naive IPF patients and 6 controls. Bulk RNA-seq was performed on bronchoalveolar lavage fluid (BALF), while single-cell RNA-seq analyzed lung tissues from 4 IPF patients and 3 controls. Differentially expressed genes (DEGs) were identified (|log2FC| >1, FDR <0.05), followed by functional enrichment, protein-protein interaction (PPI) network analysis, and cell-type-specific expression profiling. Results: 1. DEG Identification: Bulk RNA-seq revealed 108 DEGs (24 upregulated, 84 downregulated). KEGG enrichment analysis of DEGs revealed that upregulated genes were mainly enriched in inflammation and immune pathways (such as NF-κB signaling pathway, Fc epsilon RI signaling pathway, B cell receptor signaling pathway, phagosome, Fc gamma R-mediated phagocytosis), pyrimidine metabolism, cell cycle, and PI3K-Akt signaling pathway. 2. PPI Network: Module analysis identified a proliferative gene module 1 (NUF2, CEP55, ANLN, TTK, TK1, MYBL2, CCNA2, RRM2, CDT1) linked to cell division and cycle regulation. 3. Single-Cell Insights: scRNA-seq of 30,477 cells delineated 11 populations. Module 1 genes exhibited predominant expression in proliferating cells, Module 1 signature score of proliferating cells was significantly higher in IPF than in control group. 4. Pathogenic Links: Key genes (e.g., CEP55, TTK) were associated with PI3K/AKT signaling, epithelial-mesenchymal transition (EMT), and anti-apoptotic pathways, mirroring oncogenic mechanisms. Conclusion: This multi-omics approach uncovers a proliferation-centric gene module in IPF, revealing shared molecular pathways with tumorigenesis. Our findings highlight novel diagnostic biomarkers and suggest repurposing cell cycle inhibitors as potential therapies. Future studies should validate these targets in preclinical models to advance precision medicine for IPF.
Open AccessA novel proliferative candidate genes panel for idiopathic pulmonary fibrosis: insights from integrated bulk and single-cell RNA sequencing
Background: Idiopathic pulmonary fibrosis (IPF) remains a fatal interstitial lung disease with limited diagnostic specificity and therapeutic options. This study integrates bulk and single-cell RNA sequencing (RNA-seq) to identify novel biomarkers and elucidate molecular mechanisms underlying IPF pathogenesis. Methods: We prospectively enrolled 14 treatment-naive IPF patients and 6 controls. Bulk RNA-seq was performed on bronchoalveolar lavage fluid (BALF), while single-cell RNA-seq analyzed lung tissues from 4 IPF patients and 3 controls. Differentially expressed genes (DEGs) were identified (|log2FC| >1, FDR <0.05), followed by functional enrichment, protein-protein interaction (PPI) network analysis, and cell-type-specific expression profiling. Results: 1. DEG Identification: Bulk RNA-seq revealed 108 DEGs (24 upregulated, 84 downregulated). KEGG enrichment analysis of DEGs revealed that upregulated genes were mainly enriched in inflammation and immune pathways (such as NF-κB signaling pathway, Fc epsilon RI signaling pathway, B cell receptor signaling pathway, phagosome, Fc gamma R-mediated phagocytosis), pyrimidine metabolism, cell cycle, and PI3K-Akt signaling pathway. 2. PPI Network: Module analysis identified a proliferative gene module 1 (NUF2, CEP55, ANLN, TTK, TK1, MYBL2, CCNA2, RRM2, CDT1) linked to cell division and cycle regulation. 3. Single-Cell Insights: scRNA-seq of 30,477 cells delineated 11 populations. Module 1 genes exhibited predominant expression in proliferating cells, Module 1 signature score of proliferating cells was significantly higher in IPF than in control group. 4. Pathogenic Links: Key genes (e.g., CEP55, TTK) were associated with PI3K/AKT signaling, epithelial-mesenchymal transition (EMT), and anti-apoptotic pathways, mirroring oncogenic mechanisms. Conclusion: This multi-omics approach uncovers a proliferation-centric gene module in IPF, revealing shared molecular pathways with tumorigenesis. Our findings highlight novel diagnostic biomarkers and suggest repurposing cell cycle inhibitors as potential therapies. Future studies should validate these targets in preclinical models to advance precision medicine for IPF.
- 20 November 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1008, 178385
Roflumilast mitigates idiopathic pulmonary fibrosis via inhibition of iron accumulation and ferroptosis
- 20 November 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1008, 178385
Roflumilast mitigates idiopathic pulmonary fibrosis via inhibition of iron accumulation and ferroptosis
- Open Access
- 12 June 2025
- Published by Elsevier in Chinese Medical Journal Pulmonary and Critical Care Medicine
- Vol. 3 (2) , 97-99
I-125 brachytherapy for early-stage non-small cell lung cancer
- 12 June 2025
- Published by Elsevier in Chinese Medical Journal Pulmonary and Critical Care Medicine
- Vol. 3 (2) , 97-99
Open AccessI-125 brachytherapy for early-stage non-small cell lung cancer
- Open Access
- 1 May 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 5931-5950
Mechanisms of Acetate in Alleviating SETDB1-Linked Neuroinflammation and Cognitive Impairment in a Mouse Model of OSA
Background: Microglia-mediated neuroinflammation is crucial for obstructive sleep apnea (OSA)-induced cognitive impairment. We aimed to investigate roles of acetate (ACE) and SET domain bifurcated histone lysine methyltransferase 1 (SETDB1) in neuroinflammation of OSA. Methods: After C57BL/6J mice were exposed to OSA-associated intermittent hypoxia (IH) or normoxia for four weeks, the composition of the gut microbiota (GM) and the levels of serum short-chain fatty acids (SCFAs) were measured by 16S rRNA and GC-MS methods, respectively. To assess the effect of ACE on IH mice, glyceryl triacetate (GTA) was gavaged in IH-exposed mice and the cognitive function, microglial activation, and hippocampal neuronal death were examined. Moreover, ACE-treated BV2 microglia cells were also utilized for further mechanistic studies. Results: IH disrupts the gut microbiome, reduces microbiota-SCFAs, and impairs cognitive function. Gavage with GTA significantly mitigated these cognitive deficits. Following IH exposure, we observed substantial increases in SETDB1 both in vivo and in vitro, along with elevated levels of histone H3 lysine 9 trimethylation (H3K9me3). Genetic or pharmacological inhibition of SETDB1 in microglia led to decreased induction of proinflammatory factors, as well as reduced reactive oxygen species (ROS) generation. Mechanistically, SETDB1 was found to upregulate the transcription factors p-signal transducer and activator of transcription 3 (p-STAT3) and p-NF-κB. In vitro, ACE supplementation effectively repressed high SETDB1 and H3K9me3 levels, thereby inhibiting microglial pro-inflammatory responses induced by IH. In vivo, ACE supplementation significantly reduced hippocampal levels of p-STAT3, p-NF-κB, and pro-inflammatory cytokines while also protecting neuronal integrity. Conclusion: This study provides the first evidence that H3K9 methyltransferase SETDB1 promotes microglial pro-inflammatory response distinct from its previously shown role in macrophages. Our findings also identify ACE supplementation as a promising dietary intervention for OSA-related cognitive impairment with SETDB1 serving as both a mechanistic biomarker and potential therapeutic target.
- 1 May 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 5931-5950
Open AccessMechanisms of Acetate in Alleviating SETDB1-Linked Neuroinflammation and Cognitive Impairment in a Mouse Model of OSA
Background: Microglia-mediated neuroinflammation is crucial for obstructive sleep apnea (OSA)-induced cognitive impairment. We aimed to investigate roles of acetate (ACE) and SET domain bifurcated histone lysine methyltransferase 1 (SETDB1) in neuroinflammation of OSA. Methods: After C57BL/6J mice were exposed to OSA-associated intermittent hypoxia (IH) or normoxia for four weeks, the composition of the gut microbiota (GM) and the levels of serum short-chain fatty acids (SCFAs) were measured by 16S rRNA and GC-MS methods, respectively. To assess the effect of ACE on IH mice, glyceryl triacetate (GTA) was gavaged in IH-exposed mice and the cognitive function, microglial activation, and hippocampal neuronal death were examined. Moreover, ACE-treated BV2 microglia cells were also utilized for further mechanistic studies. Results: IH disrupts the gut microbiome, reduces microbiota-SCFAs, and impairs cognitive function. Gavage with GTA significantly mitigated these cognitive deficits. Following IH exposure, we observed substantial increases in SETDB1 both in vivo and in vitro, along with elevated levels of histone H3 lysine 9 trimethylation (H3K9me3). Genetic or pharmacological inhibition of SETDB1 in microglia led to decreased induction of proinflammatory factors, as well as reduced reactive oxygen species (ROS) generation. Mechanistically, SETDB1 was found to upregulate the transcription factors p-signal transducer and activator of transcription 3 (p-STAT3) and p-NF-κB. In vitro, ACE supplementation effectively repressed high SETDB1 and H3K9me3 levels, thereby inhibiting microglial pro-inflammatory responses induced by IH. In vivo, ACE supplementation significantly reduced hippocampal levels of p-STAT3, p-NF-κB, and pro-inflammatory cytokines while also protecting neuronal integrity. Conclusion: This study provides the first evidence that H3K9 methyltransferase SETDB1 promotes microglial pro-inflammatory response distinct from its previously shown role in macrophages. Our findings also identify ACE supplementation as a promising dietary intervention for OSA-related cognitive impairment with SETDB1 serving as both a mechanistic biomarker and potential therapeutic target.
- Open Access
- 26 January 2025
- Published by Elsevier in Cellular Signalling
- Vol. 128, 111630
TFEB-dependent autophagy-lysosomal pathway is required for NRF2-driven antioxidative action in obstructive sleep apnea-induced neuronal injury
- 26 January 2025
- Published by Elsevier in Cellular Signalling
- Vol. 128, 111630
Open AccessTFEB-dependent autophagy-lysosomal pathway is required for NRF2-driven antioxidative action in obstructive sleep apnea-induced neuronal injury
- Open Access
- 9 January 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (1) , e70306
The histone demethylase KDM6B links obstructive sleep apnea to idiopathic pulmonary fibrosis
Obstructive sleep apnea (OSA) is increasingly recognized for its link to idiopathic pulmonary fibrosis (IPF), though the underlying mechanisms remain poorly understood. Histone lysine demethylase 6B (KDM6B) may either prevent or promote organ fibrosis, but its specific role in IPF is yet to be clarified. This study aimed to investigate the function and mechanisms of KDM6B in IPF and the exacerbating effects of OSA. We assessed KDM6B levels in lung tissues from IPF patients, IPF mouse models, and a dual‐hit model combining OSA‐associated intermittent hypoxia (IH) with bleomycin (BLM) or TGF‐β1. We evaluated pulmonary fibrosis, myofibroblast activation, and oxidative stress. KDM6B levels were elevated in lung tissues from IPF patients and BLM‐treated mice, as well as in TGF‐β1‐stimulated myofibroblasts. Importantly, IH significantly worsened BLM‐induced pulmonary fibrosis and TGF‐β1‐induced myofibroblast activation, further amplifying KDM6B expression both in vivo and in vitro. Inhibition of KDM6B reduced pulmonary fibrosis and decreased fibroblast activation and migration in IPF and dual‐hit models. Mechanistically, KDM6B inhibition led to decreased NOX4 expression and reduced oxidative stress. KDM6B plays a critical role in promoting pulmonary fibrosis and mediating the exacerbating effects of OSA on this condition. Our findings identify KDM6B as a novel potential therapeutic target for IPF.
- 9 January 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (1) , e70306
Open AccessThe histone demethylase KDM6B links obstructive sleep apnea to idiopathic pulmonary fibrosis
Obstructive sleep apnea (OSA) is increasingly recognized for its link to idiopathic pulmonary fibrosis (IPF), though the underlying mechanisms remain poorly understood. Histone lysine demethylase 6B (KDM6B) may either prevent or promote organ fibrosis, but its specific role in IPF is yet to be clarified. This study aimed to investigate the function and mechanisms of KDM6B in IPF and the exacerbating effects of OSA. We assessed KDM6B levels in lung tissues from IPF patients, IPF mouse models, and a dual‐hit model combining OSA‐associated intermittent hypoxia (IH) with bleomycin (BLM) or TGF‐β1. We evaluated pulmonary fibrosis, myofibroblast activation, and oxidative stress. KDM6B levels were elevated in lung tissues from IPF patients and BLM‐treated mice, as well as in TGF‐β1‐stimulated myofibroblasts. Importantly, IH significantly worsened BLM‐induced pulmonary fibrosis and TGF‐β1‐induced myofibroblast activation, further amplifying KDM6B expression both in vivo and in vitro. Inhibition of KDM6B reduced pulmonary fibrosis and decreased fibroblast activation and migration in IPF and dual‐hit models. Mechanistically, KDM6B inhibition led to decreased NOX4 expression and reduced oxidative stress. KDM6B plays a critical role in promoting pulmonary fibrosis and mediating the exacerbating effects of OSA on this condition. Our findings identify KDM6B as a novel potential therapeutic target for IPF.
- 28 August 2024
- Published by Springer Nature in Infection
- Vol. 53 (1) , 307-315
Enterococci independently increase the risk for initial antibiotic treatment failure and prolonged hospitalization in adult patients with complicated urinary tract infection: a retrospective cohort study
Objectives We aimed to investigate the impact of enterococci on initial antibiotic treatment (IAT) failure and prolonged hospitalization in complicated urinary tract infection (cUTI) cases, and to identify risk factors for enterococcal cUTI. Methods Adult cUTI patients were analyzed to compare the differences between the Enterococcus and non-Enterococcus groups. Univariate and multivariate analyses were employed to identify independent risk factors. Results This study included 419 patients, with the Enterococcus group showing significantly higher IAT failure rates and an extended average length of stay by 4.4 days compared to the non-Enterococcus group. Multivariate analysis identified enterococci, hospital-acquired UTIs (HA-UTI), indwelling catheters, and bed rest (bedridden) as independent risk factors for IAT failure. Enterococci were notably linked to prolonged hospitalization, other independent risk factors included IAT failure, prior antimicrobial use, age-adjusted Charlson comorbidity index (ACCI) ≥ 4, hypoalbuminemia, and bed rest. Urological cancer, HA-UTI, indwelling catheters, urinary retention, and urologic surgery were risk factors for enterococcal cUTI. Conclusion We provide the first evidence that enterococci independently increase the risk for IAT failure and prolonged hospitalization in adults with cUTIs, highlighting the significance of timely identification to optimize measures including antibiotic regimens. Risk factors for enterococcal cUTI have also been identified to aid clinicians in managing this condition.
- 28 August 2024
- Published by Springer Nature in Infection
- Vol. 53 (1) , 307-315
Enterococci independently increase the risk for initial antibiotic treatment failure and prolonged hospitalization in adult patients with complicated urinary tract infection: a retrospective cohort study
Objectives We aimed to investigate the impact of enterococci on initial antibiotic treatment (IAT) failure and prolonged hospitalization in complicated urinary tract infection (cUTI) cases, and to identify risk factors for enterococcal cUTI. Methods Adult cUTI patients were analyzed to compare the differences between the Enterococcus and non-Enterococcus groups. Univariate and multivariate analyses were employed to identify independent risk factors. Results This study included 419 patients, with the Enterococcus group showing significantly higher IAT failure rates and an extended average length of stay by 4.4 days compared to the non-Enterococcus group. Multivariate analysis identified enterococci, hospital-acquired UTIs (HA-UTI), indwelling catheters, and bed rest (bedridden) as independent risk factors for IAT failure. Enterococci were notably linked to prolonged hospitalization, other independent risk factors included IAT failure, prior antimicrobial use, age-adjusted Charlson comorbidity index (ACCI) ≥ 4, hypoalbuminemia, and bed rest. Urological cancer, HA-UTI, indwelling catheters, urinary retention, and urologic surgery were risk factors for enterococcal cUTI. Conclusion We provide the first evidence that enterococci independently increase the risk for IAT failure and prolonged hospitalization in adults with cUTIs, highlighting the significance of timely identification to optimize measures including antibiotic regimens. Risk factors for enterococcal cUTI have also been identified to aid clinicians in managing this condition.
- Open Access
- 13 February 2024
- Published by Hindawi Limited in Case Reports in Medicine
- Vol. 2024, 1-6
Blindness in Right Eyes after Enema: A Case of Klebsiella pneumoniae-Related Invasive Liver Abscess Syndrome with Endophthalmitis-Caused Blindness as the First Symptom
We report a case of Klebsiella pneumoniae invasive liver abscess syndrome (KPILAS) with endophthalmitis-caused blindness as the first symptom after enema. The patient had diabetes, and his blood glucose was poorly controlled. She developed hematuria after four enemas for cosmetic purposes and later became blind. The eye discharge was cultured, which revealed a Klebsiella pneumoniae infection. B ultrasound did not show liver lesions, but computed tomography exhibited abscesses in the right lobe of the liver. Magnetic resonance imaging of the head indicated abscesses. These confirmed the diagnosis of invasive liver abscess syndrome. The patient was given ophthalmic and systemic anti-infection treatments, and her condition was effectively controlled. Unfortunately, the diseased eye still needed to be removed. This case underlines the necessity of avoiding unnecessary risky procedures (such as enemas) in vulnerable populations, the importance of early detection of invasive liver abscess syndrome, and the advantage of computed tomography in detecting liver abscesses.
- 13 February 2024
- Published by Hindawi Limited in Case Reports in Medicine
- Vol. 2024, 1-6
Open AccessBlindness in Right Eyes after Enema: A Case of Klebsiella pneumoniae-Related Invasive Liver Abscess Syndrome with Endophthalmitis-Caused Blindness as the First Symptom
We report a case of Klebsiella pneumoniae invasive liver abscess syndrome (KPILAS) with endophthalmitis-caused blindness as the first symptom after enema. The patient had diabetes, and his blood glucose was poorly controlled. She developed hematuria after four enemas for cosmetic purposes and later became blind. The eye discharge was cultured, which revealed a Klebsiella pneumoniae infection. B ultrasound did not show liver lesions, but computed tomography exhibited abscesses in the right lobe of the liver. Magnetic resonance imaging of the head indicated abscesses. These confirmed the diagnosis of invasive liver abscess syndrome. The patient was given ophthalmic and systemic anti-infection treatments, and her condition was effectively controlled. Unfortunately, the diseased eye still needed to be removed. This case underlines the necessity of avoiding unnecessary risky procedures (such as enemas) in vulnerable populations, the importance of early detection of invasive liver abscess syndrome, and the advantage of computed tomography in detecting liver abscesses.